Jane Street
GANX icon

Jane Street’s Gain Therapeutics GANX Stock Holding History

Jane Street’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$84.4K Buy
41,600
+3,000
+8% +$5.53K ﹤0.01% 10689
2026
Q1 		$74.9K Buy
+38,600
New +$84K ﹤0.01% 10787

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PCM
Potomac Capital Management New York $147M AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jane Street's GANX Position: Q2 2026 in Review

Jane Street reduced its Gain Therapeutics (GANX) stake by 74% in Q2 2026, selling an estimated $297K and leaving 55,628 shares worth $113K. The position accounts for ﹤0.01% of the portfolio, ranked #10527.

Jane Street first reported a position in GANX in Q1 2021 and has held it in 6 quarters since. The position peaked at $780K in Q4 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

  • Jane Street held 55,628 shares of Gain Therapeutics worth $113K as of Q2 2026.
  • Jane Street sold 161,255 Gain Therapeutics shares in Q2 2026, an estimated $297K.
  • Gain Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #10527 holding.
  • Jane Street first reported a position in Gain Therapeutics in Q1 2021 and has held it in 6 quarters since.
  • Jane Street's Gain Therapeutics position peaked at $780K in Q4 2025.
  • 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.